The concordant reduction in PHA diameter and tumor vascularity score provides angiographic evidence of VEGFR inhibition-mediated vascular remodeling, offering mechanistic insight into the synergistic antitumor effects of this regimen and supporting LEN-New FP as a promising multimodal strategy within the evolving landscape of HCC treatment. The gene discussed is KDR; the disease is neoplasm.